文献速递流行病学与生物统计临床试验与 GCP新药、器械与细胞基因治疗研发

高铁血红蛋白作为间日疟原虫伯氨喹抗休眠子活性的替代标志物:系统综述与个体患者数据荟萃分析

Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.
PubMed 文献 · PLoS Med · 2024-09-27

该系统综述与个体患者数据荟萃分析纳入8项随机平行臂临床试验、1747例葡萄糖-6-磷酸脱氢酶活性正常的间日疟患者,评估第7天高铁血红蛋白百分比与间日疟复发风险的关系。结果显示,在给定伯氨喹方案下,第7天高铁血红蛋白百分比每翻倍,间日疟复发风险估计降低30%(调整风险比=0.70,95%CI 0.57-0.86,p=0.0005)。作者认为,在葡萄糖-6-磷酸脱氢酶活性正常的间日疟患者中,高铁血红蛋白可作为伯氨喹抗休眠子活性的人群水平替代终点。

要点

  • 在葡萄糖-6-磷酸脱氢酶活性正常的间日疟患者中,第7天高铁血红蛋白百分比翻倍与复发风险估计降低30%相关(调整风险比=0.70,95%CI 0.57-0.86,p=0.0005)。
  • 每日按体重调整的伯氨喹剂量与第7天高铁血红蛋白水平之间存在递增的剂量-反应关系。
  • 以第7天高铁血红蛋白作为复发替代终点,所需样本量约减少40%。

核心结论

  • 在给定伯氨喹方案下,第7天高铁血红蛋白较高与间日疟复发风险降低相关。
  • 在作者提出的因果模型下,这支持将高铁血红蛋白作为葡萄糖-6-磷酸脱氢酶活性正常的间日疟患者中伯氨喹抗休眠子活性的人群水平替代终点。

研究设计与样本

  • 系统检索Medline、Embase、Web of Science和Cochrane Library从2000年1月1日至2022年9月29日的前瞻性临床疗效研究。
  • 纳入急性、无并发症间日疟原虫单一感染并接受伯氨喹根治剂量治疗的研究。
  • 共识别219项间日疟疗效研究,其中8项提供伯氨喹治疗患者的个体数据,均为随机平行臂临床试验且偏倚风险评为低或中等。
  • 主要分析数据集纳入来自8个国家24个研究中心的1747例葡萄糖-6-磷酸脱氢酶活性正常患者。
  • 采用带研究中心随机效应的多变量Cox比例风险回归分析第7天高铁血红蛋白百分比(以2为底对数转换)与首次复发时间的关系。

主要发现

  • 每日按体重调整的伯氨喹剂量与第7天高铁血红蛋白水平之间呈递增的剂量-反应关系。
  • 在给定伯氨喹剂量方案下,第7天高铁血红蛋白百分比观察值翻倍与间日疟复发风险估计降低30%相关(调整风险比=0.70,95%CI 0.57-0.86,p=0.0005)。
  • 上述汇总估计在各研究中心之间基本一致。
  • 以第7天高铁血红蛋白作为复发替代终点可使所需样本量约减少40%。

关键数值与推荐

  • 主要替代结局为第7天高铁血红蛋白浓度。
  • 主要临床结局为入组后第7天至第120天之间首次间日疟原虫复发的时间。
  • 模型调整了伙伴杀裂殖体药物、作为伯氨喹总剂量(mg碱基/kg)代理的伯氨喹疗程时长、每日伯氨喹剂量(mg/kg)及其他因素。
  • 系统综述方案在PROSPERO注册(CRD42023345956)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究局限性包括无法区分间日疟复发中的再燃、再感染和复燃。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 8-aminoquinolines, primaquine and tafenoquine, are the only available drugs for the radical cure of Plasmodium vivax hypnozoites. Previous evidence suggests that there is dose-dependent 8-aminoquinoline induced methaemoglobinaemia and that higher methaemoglobin concentrations are associated with a lower risk of P. vivax recurrence. We undertook a systematic review and individual patient data meta-analysis to examine the utility of methaemoglobin as a population-level surrogate endpoint for 8-aminoquinoline antihypnozoite activity to prevent P. vivax recurrence. METHODS AND FINDINGS: We conducted a systematic search of Medline, Embase, Web of Science, and the Cochrane Library, from 1 January 2000 to 29 September 2022, inclusive, of prospective clinical efficacy studies of acute, uncomplicated P. vivax malaria mono-infections treated with radical curative doses of primaquine. The day 7 methaemoglobin concentration was the primary surrogate outcome of interest. The primary clinical outcome was the time to first P. vivax recurrence between day 7 and day 120 after enrolment. We used multivariable Cox proportional-hazards regression with site random-effects to characterise the time to first recurrence as a function of the day 7 methaemoglobin percentage (log base 2 transformed), adjusted for the partner schizonticidal drug, the primaquine regimen duration as a proxy for the total primaquine dose (mg base/kg), the daily primaquine dose (mg/kg), and other factors. The systematic review protocol was registered with PROSPERO (CRD42023345956). We identified 219 P. vivax efficacy studies, of which 8 provided relevant individual-level data from patients treated with primaquine; all were randomised, parallel arm clinical trials assessed as having low or moderate risk of bias. In the primary analysis data set, there were 1,747 patients with normal glucose-6-phosphate dehydrogenase (G6PD) activity enrolled from 24 study sites across 8 different countries (Indonesia, Brazil, Vietnam, Thailand, Peru, Colombia, Ethiopia, and India). We observed an increasing dose-response relationship between the daily weight-adjusted primaquine dose and day 7 methaemoglobin level. For a given primaquine dose regimen, an observed doubling in day 7 methaemoglobin percentage was associated with an estimated 30% reduction in the risk of P. vivax recurrence (adjusted hazard ratio = 0.70; 95% confidence interval [CI] [0.57, 0.86]; p = 0.0005). These pooled estimates were largely consistent across the study sites. Using day 7 methaemoglobin as a surrogate endpoint for recurrence would reduce required sample sizes by approximately 40%. Study limitations include the inability to distinguish between recrudescence, reinfection, and relapse in P. vivax recurrences. CONCLUSIONS: For a given primaquine regimen, higher methaemoglobin on day 7 was associated with a reduced risk of P. vivax recurrence. Under our proposed causal model, this justifies the use of methaemoglobin as a population-level surrogate endpoint for primaquine antihypnozoite activity in patients with P. vivax malaria who have normal G6PD activity.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Fadilah I, Commons RJ, Chau NH, et al. Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis. PLoS Med. 2024. PMID: 39331646. doi:10.1371/journal.pmed.1004411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。